High amyloid has been associated with substantial episodic memory decline over 18 and 36 months in healthy older adults and individuals with mild cognitive impairment. However, the nature and magnitude of amyloid-related memory and non-memory change from the preclinical to the clinical stages of Alzheimer's disease has not been evaluated over the same time interval. Healthy older adults (n = 320), individuals with mild cognitive impairment (n = 57) and individuals with Alzheimer's disease (n = 36) enrolled in the Australian Imaging, Biomarkers and Lifestyle study underwent at least one positron emission tomography neuroimaging scan for amyloid. Cognitive assessments were conducted at baseline, and 18-and 36-month follow-up assessments. Compared with amyloid-negative healthy older adults, amyloid-positive healthy older adults, and amyloid-positive individuals with mild cognitive impairment and Alzheimer's disease showed moderate and equivalent decline in verbal and visual episodic memory over 36 months (d's = 0.47-0.51). Relative to amyloid-negative healthy older adults, amyloid-positive healthy older adults showed no decline in non-memory functions, but amyloid-positive individuals with mild cognitive impairment showed additional moderate decline in language, attention and visuospatial function (d's = 0.47-1.12), and amyloid-positive individuals with Alzheimer's disease showed large decline in all aspects of memory and non-memory function (d's = 0.73-2.28). Amyloid negative individuals with mild cognitive impairment did not show any cognitive decline over 36 months. When non-demented individuals (i.e. healthy older adults and adults with mild cognitive impairment) were further dichotomized, high amyloid-positive non-demented individuals showed a greater rate of decline in episodic memory and language when compared with low amyloid positive non-demented individuals. Memory decline does not plateau with increasing disease severity, and decline in non-memory functions increases in amyloid-positive individuals with mild cognitive impairment and Alzheimer's disease. The combined detection of amyloid positivity and objectively-defined decline in memory are reliable indicators of early Alzheimer's disease, and the detection of decline in nonmemory functions in amyloid-positive individuals with mild cognitive impairment may assist in determining the level of disease severity in these individuals. Further, these results suggest that grouping amyloid data into at least two categories of abnormality may be useful in determining the disease risk level in non-demented individuals.
Introduction
Recent prospective studies show that amyloid-b positivity, as detected by PET neuroimaging, is associated with substantial decline in episodic memory decline over 18 and 36 months in individuals who meet clinical criteria for mild cognitive impairment (MCI) as well as in otherwise healthy older adults, even in the absence of any change in clinical disease status Doraiswamy et al., 2012; Lim et al., 2012 Lim et al., , 2013a Small et al., 2012; Ellis et al., 2013) . In contrast, healthy older adult and MCI groups with low amyloid-b show no deterioration in episodic memory over the same time intervals Lim et al., 2012 Lim et al., , 2013a Ellis et al., 2013) . In MCI, the amyloid-b-related memory decline confirms that the clinical abnormalities observed are indicative of incipient Alzheimer's disease (Dubois and Albert, 2004; Albert et al., 2011) , whereas in healthy older adults, it shows that Alzheimer's disease-related neurodegeneration can be detected years before individuals meet any clinical staging criteria for early Alzheimer's disease (Mintun et al., 2006; Aizenstein et al., 2008; Rowe et al., 2010) .
Recent pathophysiological models of Alzheimer's disease show that amyloid-b accumulation slows once individuals meet clinical criteria for Alzheimer's disease (Jack et al., 2010 (Jack et al., , 2013 Bateman et al., 2012; Villemagne et al., 2013) . Further, although cross-sectional studies report robust negative associations between amyloid-b and memory in MCI, no such associations are observed in Alzheimer's disease (Pike et al., 2007; Mormino et al., 2008) . It is possible, therefore, that when compared to the rate of amyloid-b accumulation observed in non-demented individuals, the rate of cognitive decline may also decrease once clinical criteria for Alzheimer's disease are met (Jack et al., 2010; Bateman et al., 2012) . However, as yet, the nature and magnitude of amyloid-b-related cognitive change in the preclinical and clinical stages of Alzheimer's disease have not been compared directly. Further, in the majority of studies from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study cohort, amyloid-b-related memory decline has been characterized using a single neuropsychological test of episodic memory (e.g. verbal list learning; Ellis et al., 2013) , an episodic memory composite score (Villemagne et al., , 2013 , or with a brief computerized cognitive test battery (i.e. CogState brief battery; Lim et al., 2012 Lim et al., , 2013a . Although these data provide converging evidence that in non-demented individuals, amyloid-b positivity is associated with episodic memory decline, there has been no thorough investigation of the extent to which any amyloid-b-related decline extends to other aspects of cognition (e.g. attention, language and executive function). Further, as decline in cognition is the hallmark of clinically diagnosed Alzheimer's disease (Almkvist, 1996; Mohs et al., 2000; Minati et al., 2009) , it provides a strong basis for comparison of the nature and magnitude of cognitive decline in the preclinical and prodromal stages of the disease.
The aim of this study was to investigate the nature and magnitude of change in a comprehensive range of neuropsychological outcomes over 36 months in individuals with Alzheimer's disease, patients with amnestic MCI and in healthy older adults with a positive and negative amyloid-b scan. The first hypothesis was that all aspects of cognition would remain stable over 36 months in healthy older adults and in individuals with amnestic MCI who are amyloidb À . The second hypothesis was that amyloid-b positivity in healthy older adults and in individuals with MCI or Alzheimer's disease would be associated with a significant decline in memory over 36 months. We then explored the extent to which changes in other aspects of cognition were associated with amyloid-b positivity and whether these changes differed according to clinical group. Further, as previous studies have reported an effect of apolipoprotein (APOE) e4 carriage on cognitive decline (Caselli et al., 2009; Lim et al., 2012; Ellis et al., 2013) , we explored whether APOE e4 moderated any cognitive decline associated with amyloid-b positivity. Finally, as we have shown previously that non-demented individuals who have high amyloid-b positivity [e.g. standardized uptake value (SUV) ratio 5 1.9] progress to MCI or Alzheimer's disease at a faster rate than non-demented individuals who have low amyloid-b positivity (e.g. SUV ratio 1.5-1.9) (Rowe et al., 2013a) , we explored the extent to which the level of amyloid-b positivity affects rates of cognitive decline over 36 months.
Materials and methods

Participants
All participants in the current study were recruited from the AIBL Study of Ageing (Ellis et al., 2009; Rowe et al., 2010) . The process of recruitment and diagnosis classification has been described in detail previously (Ellis et al., 2009) . In this study, only healthy older adults and individuals with MCI or Alzheimer's disease who had undergone amyloid-b imaging with PET and who had completed the AIBL neuropsychological battery at baseline and at 18-month and 36-month follow-up were included. Demographic characteristics of each participant group are shown in Table 1 .
All participants with Alzheimer's disease met NINCDS-ADRDA criteria for Alzheimer's disease (McKhann et al., 1984) , and in all cases, the clinical review panel (chaired by D.A.) reviewed all available data to ensure that the diagnosis was consistent with these agreed criteria. Similarly, all available data for participants with MCI were reviewed to ensure that their classification was consistent with internationally agreed criteria (Petersen et al., 1999; Winblad et al., 2004) . For participants with Alzheimer's disease, an additional inclusion criterion was a score of 18 to 26 on the Mini-Mental State Examination (Folstein et al., 1975) . All participants with Alzheimer's disease and MCI received a Clinical Dementia Rating scale sum of boxes score and a total score (Morris, 1983) . Exclusion criteria at baseline were: schizophrenia; depression (Geriatric Depression Score of 56); Parkinson's disease; cancer (other than basal cell skin carcinoma) within the past 2 years; symptomatic stroke; uncontrolled diabetes; or current regular alcohol use exceeding two standard drinks per day for women or four per day for men. Clinical classification was blinded to amyloid-b imaging data.
The study was approved by and complied with the regulations of the institutional research and ethics committees of Austin Health, St. Vincent's Health, Hollywood Private Hospital and Edith Cowan University (Ellis et al., 2009) . All participants provided written informed consent before participating in the study.
Measures
Positron emission tomography neuroimaging and APOE e4 genotyping F-flutemetamol. PET methodology has been described in detail previously (Rowe et al., 2010; Vandenberghe et al., 2010; Wong et al., 2010) . Given the different pharmacokinetic characteristics, a different acquisition protocol was adopted for each tracer. Thirty minute acquisitions were started 40 min after injection of Pittsburgh compound B, 20-min acquisitions were performed 50 min after injection of florbetapir and 90 min after injection of flutemetamol. For Pittsburgh compound B and flutemetamol, PET SUV data were summed and normalized to the cerebellar cortex SUV, resulting in a region-to-cerebellar ratio termed SUV ratio. For florbetapir, the SUV ratio was generated using the whole cerebellum as the reference region (Clark et al., 2011) . In line with previous studies, the SUV ratio was classified dichotomously as either negative or positive. For Pittsburgh compound B and flutemetamol, a SUV ratio threshold 51.5 was used (Rowe et al., 2010; Vandenberghe et al., 2010) . In the case of florbetapir, based on the results of a phase III study (Clark et al., 2011) , an SUV ratio threshold of 51.1 was used to discriminate between amyloid-b À and amyloid-b + . As participants were scanned at different follow-up time points (Table 1) , we classified participants as amyloid-b À or amyloid-b + based on the SUV ratio that was obtained closest to their 36 month follow-up time point.
An 80 ml blood sample was also taken from each participant, 0.5 ml of which was forwarded for APOE genotyping at a clinical pathology laboratory.
Cognitive and clinical assessments
All participants were assessed with the clinical rating scales and neuropsychological battery from the AIBL study which have been described in detail elsewhere (Ellis et al., 2009; Rowe et al., 2010) . The clinical status of participants was determined by data which included the Mini-Mental State Examination (Folstein et al., 1975) , and the Clinical Dementia Rating scale (Morris, 1983) . Premorbid intelligence was estimated using the Wechsler Test of Adult Reading (Wechsler, 2001) , and levels of depressive and anxiety symptoms were assessed using the Hospital Anxiety and Depression (Snaith and Zigmond, 1986) .
Procedure
Participants underwent an extensive medical, psychiatric, and neuropsychological assessment upon enrolment into the AIBL study. The same Of the 320 healthy adults who underwent PET neuroimaging, 178 were scanned using 11 C-Pittsburgh compound B, 73 using 18 F florbetapir, and 69 using 18 F flutemetamol.
Of the 57 adults with MCI who underwent PET neuroimaging, 49 were scanned using 11 C Pittsburgh compound B, four using 18 F florbetapir, and four using 18 F flutemetamol. Of the 36 adults with Alzheimer's disease who underwent PET neuroimaging, 35 were scanned using 11 C Pittsburgh compound B, and one using 18 F florbetapir. Participants who underwent PET neuroimaging using Pittsburgh compound B were scanned at baseline and at each 18 month follow-up time point. Participants who underwent PET neuroimaging using florbetapir or flutemetamol were scanned at the 36 month follow-up time point.
assessments were repeated 18 and 36 months after baseline. In this study, we report PET neuroimaging and APOE e4 genotyping data obtained at baseline, and neuropsychological data obtained at baseline, 18 months and 36 months to examine the rate of cognitive change in relation to baseline levels of amyloid-b.
Data analysis
Individual outcome measures on individual tests were standardized against the baseline mean and standard deviation for the healthy older adult group, and then averaged to compute a cognitive com- Figure Test Copy, and Clock Drawing). The process of selecting cognitive tasks for the formation of each composite score, and the validation of each cognitive composite score has been described in detail previously . A series of repeated measures linear mixed model analyses (using maximum likelihood estimation and an unstructured covariance matrix) were conducted to examine the relation between group [healthy older adult amyloid-bÀ (HA-Ab À ), healthy older adult amyloid-b + (HAAb + ), MCI amyloid-bÀ (MCI-Ab À), MCI amyloid-b + (MCI-Ab + ) and Alzheimer's disease amyloid-b + (AD-Ab + )] and time (baseline, 18 month, and 36 month) on cognitive change. Linear mixed modelling was used because of its ability to model both fixed and random effects, which accounts for multiple sources of variability, and because it provides improved estimates of within-subject coefficients (i.e. random effects) in longitudinal studies. In these analyses, group, time, APOE status (e4 carrier, e4 non-carrier), and the group Â time interaction were entered as fixed factors; participant as a random factor; age and premorbid intelligence as covariates; and cognitive composite score as the dependent variable. For each cognitive composite score, mean slope estimates were computed for each group. The magnitude of difference in the rates of change (i.e. slopes) of the HA-Ab + , MCI-Ab À, MCI-Ab + , and AD-Ab + groups in relation to the HA-Ab À group was expressed using Cohen's d and 95% confidence intervals (CIs) (Cohen, 1988) .
To investigate whether there was an effect of APOE e4 on amyloidb-related change in cognition, and to maximize the power to detect any subtle relationships, participants were classified into amyloid-bÀ (HA-AbÀ , MCI-Ab À) and amyloid-b + (HA-Ab + , MCI-Ab + ) groups. The AD-Ab + group was excluded from this analysis, as there were no individuals with Alzheimer's disease that were amyloid-b À. Linear mixed model analyses were then conducted to examine the relationship between group (amyloid-b À, amyloid-b + ), APOE (e4 carrier, e4 non-carrier), and time (baseline, 18 months, and 36 months) on change in each cognitive composite score. In these analyses, only main effects or interactions involving APOE were interpreted.
To determine whether level of amyloid-b positivity (i.e. high amyloid-b + or low amyloid-b + ) was associated with increased rates of cognitive decline in non-demented individuals, we combined the HAAb + and MCI-Ab + groups. Receiver operating characteristic analysis of the AIBL Alzheimer's disease and healthy older adult cohorts were also performed (Rowe et al., 2013a) . This indicated that for Pittsburgh compound B, an SUV ratio of 1.9 was the optimal cut-off point for distinction of individuals with Alzheimer's disease from age-matched healthy older adult. Thus, this higher SUV ratio cut-off point was used to define high amyloid-b + and low amyloid-b + (SUV ratio 1.5-1.9). Similarly, for flutemetamol, an SUV ratio threshold 52.19 was used to discriminate between high amyloid-b + and low amyloid-b + (SUV ratio 1.5-2.19) non-demented individuals, and for florbetapir, the SUV ratio threshold used was 51.29. Linear mixed model analyses were conducted to examine the relationship between amyloid-b positivity (low amyloidb + versus high amyloid-b + ) and time (baseline, 18 months and 36 months) on change in each cognitive composite score.
Results
Demographic differences between amyloid-b À and amyloid-b + subgroups in healthy older adults, mild cognitive impairment and Alzheimer's disease There were statistically significant differences between the five groups in age and premorbid intelligence. In particular, the MCIAbÀ and AD-Ab + groups had significantly lower premorbid intelligence when compared with the HA-AbÀ , HA-Ab + and MCIAb + groups, P 5 0.001. The HA-AbÀ and HA-Ab + groups were also significantly younger than the MCI-AbÀ and MCI-Ab + groups, P 5 0.05. Groups did not differ on symptoms of depression or anxiety (Table 1 ). There were significantly more APOE e4 carriers in both the HA-Ab + and MCI-Ab + groups.
Comparison of rates of cognitive change in HA-Ab + , MCI-AbÀ , MCI-Ab + and AD-Ab + groups relative to the HA-Ab À group Group Â time interactions were statistically significant for all cognitive composite scores (Supplementary Table 1 ). The mean slope for each clinical group for each composite is given in Table 2 . The magnitude of the difference in slopes for each group from that of the HAAbÀ group is presented for each composite score in Fig. 2. In Fig. 2 , the 95% CIs presented for each effect size also allows interpretation of significant differences (i.e. where 95% CIs do not overlap).
Post hoc comparison of group mean slopes over 36 months indicated that, relative to the HA-AbÀ group, the HA-Ab + group showed a significantly greater rate of decline over 36 months on the verbal episodic memory, and visual episodic memory composites, with the magnitude of these differences, by convention, moderate (Cohen, 1988) (Table 3 and Fig. 1A and B) . No differences in group mean slopes were observed between the HA-Ab À and HA-Ab + groups on any of the other cognitive composite scores. Similarly, relative to the HA-AbÀ group, the MCIAb + group showed a greater rate of decline over 36 months on the verbal episodic memory, and visual episodic memory composites, and also decline on the language, attention, and visuospatial function composites (Table 2 and Fig. 2) . The difference in group Table 2 Mean slopes and standard deviation of the slopes for each participant group, and the magnitude of difference in slopes of HA-Ab + , MCI-AbÀ, MCI-Ab + and AD-Ab + groups from the HA-AbÀ group mean slopes was by convention, moderate-to-large in magnitude.
Relative to the =HA-AbÀ group, the AD-Ab + group showed greater rates of decline over 36 months on all cognitive composite measures, and the magnitude of difference in group mean slopes was large (Table 2 and Fig. 2 ). Of note, the MCI-AbÀ group showed no decline on any of the cognitive composite scores relative to the HA-AbÀ group, rather, they showed improvement on the verbal episodic memory composite with this improvement, relative to the HA-AbÀ group, moderate-to-large in magnitude ( Table 2 ).
The effect of APOE e4 on the relationship between amyloid-b and cognitive change
Analysis of the effect of APOE e4 carriage on the relationship between amyloid-b and cognitive change over 36 months showed no significant interactions for any cognitive composite score (Table 3 ). The only statistically significant effect identified from this analysis was the main effect of APOE on cognitive change over 36 months for the verbal memory composite score (Table 3 ).
The effect of low or high amyloid-b positivity on cognitive change in non-demented individuals
Amyloid-b positivity Â time interactions were statistically significant for verbal and visual episodic memory and language composites (Table 4 ). Relative to low amyloid-b + non-demented individuals, high amyloid-b + non-demented individuals showed a significantly greater rate of decline over 36 months that was moderate in magnitude, for the verbal episodic memory, visual episodic memory, and language composites only (Table 4) . This analysis was then repeated in only the HA-Ab + group. When compared with the low amyloid-b + healthy older adult group, the high amyloid-b + healthy older adult showed significantly greater rate of decline over 36 months that was moderate in magnitude for the verbal episodic memory 
Discussion
The first hypothesis that all aspects of cognitive function would remain stable in healthy older adults and individuals with MCI who were amyloid-bÀ was supported partially. Specifically, amyloidbÀ healthy older adults showed no change in verbal or visual episodic memory (Fig. 1) or any other aspect of cognitive function over 36 months (Table 2) . However, amyloid-bÀ individuals with MCI showed improvement in verbal memory over 36 months that was, by convention (Cohen, 1988) , moderate-to-large in magnitude (Table 2 and Fig. 1A ). The absence of decline in memory or any other cognitive function over 36 months in amyloid-b À healthy older adults replicates and extends previous observations of cognitive stability over 6, 18 and 36 months in negative amyloid-b healthy older adults from AIBL Lim et al., 2012 Lim et al., , 2013b Ellis et al., 2013) and other cohorts (Doraiswamy et al., 2012; Small et al., 2012; Snitz et al., 2013) . In individuals with amyloid-bÀ MCI, the finding of no cognitive decline is also consistent with the results of previous 18 and 36 month studies (Doraiswamy et al., 2012; Lim et al., 2013a, b) , which converge to suggest that even when characterized clinically within a highly specialized Alzheimer's disease memory clinic, MCI without a positive amyloid-b biomarker most likely reflects neurological or psychiatric conditions other than Alzheimer's disease (Dubois and Albert, 2004) . The moderate-to-large improvements in verbal episodic memory over 36 months observed in the amyloid-bÀ MCI group suggests that the abnormality in memory observed at the baseline assessment may have reflected, at least in part, the effects of situationally-raised levels of depression or anxiety that can occur when individuals with memory difficulties are confronted with formal cognitive tests (Beaudreau and O'Hara, 2008) , the effects of subclinical mental health, sleep, or physical health. These factors may have then resolved with experience in the AIBL study, and consequently the magnitude of memory impairment was reduced. However by themselves, these factors cannot account fully for the baseline memory impairment in the amyloid-bÀ MCI group as all individuals in this group were still classified as meeting clinical criteria for MCI by a consensus panel after 36 months in the study. The second hypothesis that in healthy older adults, individuals with MCI and individuals with Alzheimer's disease, amyloid-b positivity would be associated with decline in memory over 36 months was supported. For amyloid-b + healthy older adults, the rate of decline in verbal and visual episodic memory over 36 months was moderate in magnitude when compared with memory changes in amyloid-bÀ healthy older adults (Fig. 1) . No difference between amyloid-b À or positive healthy older adults was observed in the rate of change for any cognitive function other than memory. These data confirm previous examinations of the current sample conducted over shorter time intervals or with other measures of memory (Lim et al., 2012 . They are also consistent with observations made in other prospective studies of older individuals who have elevated amyloid-b on PET neuroimaging to suggest that specific memory decline is the hallmark of preclinical Alzheimer's disease (Darby et al., 2011; Villemagne et al., 2011; Doraiswamy et al., 2012; Small et al., 2012; Snitz et al., 2013) . When compared with amyloid-b À healthy older adults, individuals with amyloid-b + MCI also showed greater rates of decline in verbal and visual episodic memory, with the magnitude of the decline moderate to large by convention (Fig. 2) . However, in amyloid-b + MCI, decline was also observed for language, attention and visuospatial function, with the magnitude of decline in these other domains of cognition equivalent to that observed for the decline in episodic memory (Fig. 2) . Finally, when compared with amyloid-b À healthy older adults, amyloid-b + patients with Alzheimer's disease showed large decline across all areas of cognitive function (Fig. 2) with the largest decline observed for language and visuospatial function.
The observation that there was substantial overlap between the confidence intervals for the magnitude of decline for amyloid-b + healthy older adult, MCI and Alzheimer's disease groups (Fig. 2) suggest that the rate of decline in verbal and visual episodic memory was equivalent between these groups over 36 months. Among amyloid-b + individuals who met clinical criteria for MCI, decline in cognition extended from memory to language, attention and visuospatial functions, with the magnitude of this decline large but equivalent across these cognitive domains. In some of our own previous studies of non-demented individuals with elevated amyloid-b (Villemagne et al., , 2013 , we have categorized cognitive functions as either memory or non-memory and observed that in general, amyloid-b-related cognitive change in non-demented older individuals was specific to episodic memory. However, results of the current study indicate that when examined more carefully, clinically significant decline occurs in cognitive domains other than memory, most notably in language and visuospatial function, among individuals with amyloid-b + MCI. One interesting aspect of these data is that no decline was observed for executive function in individuals with amyloid-b + MCI. This result contrasts with prior suggestions that impairment in executive function is an important characteristic of early Alzheimer's disease (Baudic et al., 2006; Traykov et al., 2007) . One reason for this may be that we classified individuals with early Alzheimer's disease based on the clinical classification of MCI with additional biomarker confirmation (i.e. amyloid-b positivity), whereas previous studies that have found impairment in executive function were conducted only in clinically classified MCI. Further, several authors have suggested that the presence of impairment in executive function in individuals with MCI may be indicative of a non-Alzheimer's disease aetiology (Dubois and Albert, 2004; Petersen, 2004) .
Recent pathophysiological models of Alzheimer's disease suggest that the rate of amyloid-b accumulation usually slows after individuals meet clinical criteria for Alzheimer's disease (Jack et al., 2010 (Jack et al., , 2013 Villemagne et al., 2013) . Thus, when the low amyloid-b levels of younger adults are considered, the temporal relationship between amyloid-b accumulation and age across the lifespan tends to become sigmoidal in nature (Jack et al., 2010; Bateman et al., 2012; Villemagne et al., 2013) . These same models suggest that like amyloid-b accumulation, the rate of cognitive decline may also reach a plateau once individuals meet clinical criteria for Alzheimer's disease, especially given that once individuals meet clinical criteria for Alzheimer's disease, while the association between amyloid-b burden and cognitive performance is weak or non-existent, there is a high association between the rates of amyloid-b accumulation and the rates of cognitive decline, probably reflecting the simultaneous or parallel slowing of both processes (Jack et al., 2013; Villemagne et al., 2013) . Results of the current study show that despite meeting clinical criteria for Alzheimer's disease, decline in memory continues at the same rate as that observed for non-demented amyloid-b + older individuals. However, in these same individuals who are amyloid-b + and have Alzheimer's disease, rates of decline in all non-memory domains are substantially increased when compared to those observed for amyloid-b + healthy older adults. Taken together, as decline in memory is characteristic of Alzheimer's disease even in the earliest preclinical stage (Braak and Braak, 1991; Sperling et al., 2011) , memory decline in Alzheimer's disease also persists at the same rate. However, as the disease progresses, other cognitive domains become affected and therefore, the rate of decline in the non-memory domains is more pronounced when compared to that observed in the earlier stages of the illness (i.e. preclinical stage) where there is little or no decline in these same non-memory functions. This suggests that the assessment of cognitive domains in addition to memory may provide greater insight into the disease progression of individuals once they meet clinical criteria for Alzheimer's disease.
The APOE e4 allele did not moderate the relationship between amyloid-b and decline for any cognitive domain in individuals who are amyloid-b À (amyloid-bÀ healthy older adults and individuals with MCI) or individuals who are amyloid-b + (amyloid-b + healthy older adults and individuals with MCI) (Table 4) . We have reported previously that the APOE e4 allele did not moderate amyloid-b-related decline in memory in studies conducted over shorter time intervals (i.e. 6 and 18 months) (Lim et al., 2012 (Lim et al., , 2013c Ellis et al., 2013) . In these previous studies, inclusion of APOE e4 status (e4 carrier or non-carrier) and amyloid-b status (negative or positive) in our statistical models has resulted in decline being observed for both APOE e4 and amyloid-b status (Lim et al., 2012; Ellis et al., 2013) ; however, the strength of APOE e4-related cognitive decline has always been substantially less than that observed for amyloid-b. In the current study, we observed this effect again in the combined sample of healthy older adults and individuals with MCI, assessed over a longer period of time than has been done previously. The only effect of APOE e4 status observed was that for decline in verbal episodic memory. Taken together, these data support the hypothesis that while APOE e4 carriage is a risk factor for amyloid-b positivity, once this occurs, APOE e4 does not moderate disease progression, at least at a level which can be detected by cognitive assessments.
In healthy older adults, SUV ratio has been consistently shown to have a skewed distribution, as opposed to the normal distribution typically observed in clinical and cognitive variables (Jack et al., 2008; Rowe et al., 2010) . As such, in order to parametrically determine associations between amyloid-b levels and cognitive markers, we and others have separated amyloid-b into two categories (positive and negative). However, as sample sizes of individuals who had undergone neuroimaging have grown, there is now some evidence to suggest that additional prognostic information can be derived from the degree of amyloid-b positivity. Recently, we showed that when a receiver operating characteristic analysis of healthy older adult and Alzheimer's disease groups was conducted, an SUV ratio of 51.90 was the optimal cut-off for a diagnosis of Alzheimer's disease (Rowe et al., 2013a) . Further, a high amyloid-b + scan (e.g. SUV ratio41.90) in non-demented individuals (i.e. healthy older adult and individuals with MCI) was associated with significantly higher positive predictive rates of progression to the next disease stage than a low amyloid-b + scan (e.g. SUV ratio 1.50-1.90) in non-demented individuals (Rowe et al., 2013a) . These data suggest that there is some dose-dependent effect of the level of amyloid-b positivity on memory decline in non-demented individuals. For example, nondemented individuals with higher levels of amyloid-b positivity may be closer in time to a clinical diagnosis of Alzheimer's disease (Rowe et al., 2013a; Villemagne et al., 2013) . In accord with this previous observation, the results of this study show that high amyloid-b + non-demented individuals show greater rates of decline in episodic memory and language when compared to low amyloid-b + individuals. Taken together, these results suggest that grouping data into at least two categories of abnormality may be useful in determining the disease risk level in non-demented individuals.
In this study, we have reported estimates of the mean and standard deviation of the slope for the relationship between amyloid-b and each cognitive composite score over 36 months for all stages of the disease. The finding that amyloid-b positivity is associated with cognitive decline across all stages of Alzheimer's disease accords with drug development strategies that have aimed at reducing the effect of amyloid-b on the brain. Therefore, the slope estimates presented here may serve as a guide to inform the rate of amyloid-b-related decline in cognitive function that would be expected to occur in placebo groups at each stage of the illness. Further, they could be used to estimate effect sizes and sample sizes that would be required to provide sufficient statistical power to detect the extent to which amyloid-b-modifying drugs can halt or delay amyloid-b-related cognitive decline.
An important caveat when interpreting the results of this study is that the AIBL study is not an epidemiological but a convenience sample. The selection of MCI groups was biased towards the inclusion of individuals with amnestic MCI. Further, in the recruitment of healthy older adults, participants in AIBL were highly educated, and few had existing or untreated medical, neurological, or psychiatric illnesses. As such, it would be important for these findings to be replicated in amyloid-b + individuals in populationbased samples, such as the Mayo Clinic Study of Aging (Roberts et al., 2008) , where it is possible that amyloid-b-related decline in cognition may be greater than that observed here. A second caveat is that participants who underwent 18 F-florbetapir or 18 Fflutemetamol PET imaging were scanned only at their 36-month follow-up assessment, and the number of individuals who underwent neuroimaging using the three different compounds was uneven (Table 1) . Importantly though, 11 C-PiB, 18 F-florbetapir and 18 F-flutemetamol are commonly used to measure use Ab levels (Clark et al., 2011; Rowe et al., 2013b; Vandenberghe et al., 2010) , and we have shown previously that accumulation of Ab in HA and MCI groups occur at a rate of less than 0.05 per year (Villemagne et al., 2013) . Finally, we did not consider whether healthy older adult and MCI amyloid-b + groups progressed to the next disease classification at a faster rate than amyloid-bÀ individuals. This was because the primary aim of this study was to consider the disease as a continuous process, and to determine the rate of cognitive decline associated with amyloid-b positivity in each clinical group. Further, previous studies of the same group have shown that after even after removal of individuals for whom the disease had progressed to the next stage (i.e. from healthy to MCI, or from MCI to Alzheimer's disease), decline in memory remained of equivalent magnitude (Lim et al., 2012 (Lim et al., , 2013b Ellis et al., 2013) , suggesting that this memory decline is a characteristic of individuals with amyloidb + groups, and not merely a consequence of amyloid-b + groups containing more individuals for whom the disease had progressed.
These limitations notwithstanding, results of this study suggest that the combined detection of a positive biomarker for Alzheimer's disease and objectively-defined decline in memory are reliable indicators of the earliest stages of Alzheimer's disease, and that amyloid-b positivity in individuals with MCI provides additional confirmation that the underlying aetiology is due to Alzheimer's disease. Importantly, these findings suggest that amyloid-b + healthy older adults may be promising candidates for clinical trials aiming to modify or halt the progression of Alzheimer's disease in its very early stages.
